- Home
- BAH vs RPRX Comparison
BAH vs RPRX Comparison
Compare BAH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAH
- RPRX
- Stock Information
- Founded
- BAH 1914
- RPRX 1996
- Country
- BAH United States
- RPRX United States
- Employees
- BAH N/A
- RPRX N/A
- Industry
- BAH Professional Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- BAH Consumer Discretionary
- RPRX Health Care
- Exchange
- BAH Nasdaq
- RPRX Nasdaq
- Market Cap
- BAH 13.9B
- RPRX 14.2B
- IPO Year
- BAH 2010
- RPRX 2020
- Fundamental
- Price
- BAH $123.90
- RPRX $33.15
- Analyst Decision
- BAH Buy
- RPRX Strong Buy
- Analyst Count
- BAH 12
- RPRX 4
- Target Price
- BAH $147.36
- RPRX $42.50
- AVG Volume (30 Days)
- BAH 1.7M
- RPRX 3.7M
- Earning Date
- BAH 05-23-2025
- RPRX 05-08-2025
- Dividend Yield
- BAH 1.77%
- RPRX 2.65%
- EPS Growth
- BAH 116.72
- RPRX 37.42
- EPS
- BAH 6.70
- RPRX 2.45
- Revenue
- BAH $11,776,700,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- BAH $13.99
- RPRX $31.30
- Revenue Next Year
- BAH $6.88
- RPRX $5.82
- P/E Ratio
- BAH $18.57
- RPRX $13.54
- Revenue Growth
- BAH 14.07
- RPRX 1.12
- 52 Week Low
- BAH $101.05
- RPRX $24.05
- 52 Week High
- BAH $190.59
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- BAH 69.45
- RPRX 57.43
- Support Level
- BAH $118.35
- RPRX $31.97
- Resistance Level
- BAH $124.94
- RPRX $34.11
- Average True Range (ATR)
- BAH 2.96
- RPRX 0.71
- MACD
- BAH 0.64
- RPRX 0.09
- Stochastic Oscillator
- BAH 91.80
- RPRX 62.06
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.